Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jun 16;3(3):ofw128. doi: 10.1093/ofid/ofw128

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2016. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

PMC Copyright notice

Figure 1. — Examples of the 4 main categories of (1-3)-β-d-glucan (BG) postdiagnosis kinetic profiles observed after a diagnosis of invasive aspergillosis (IA). For each example, the blue curve represents the BG kinetics before, at the time, and after a diagnosis of IA. The red cross represents the day of collection (D0) of the first biological sample that led to the diagnosis of IA: y-axis, BG values in pg/mL; x-axis, time relative to the day (D0) of collection of the sample that led to the diagnosis of IA, expressed in weeks. (A) Negative BG profile (N = 8 of 37): patients showing persistently negative BG test results after IA diagnosis. The kinetics shown are those of Patient 19 (hematology patient), who received a diagnosis of probable pulmonary IA, for whom 3 BG assays were performed before diagnosis and 6 BG assays were performed within 12 weeks of diagnosis. The first mycological result allowing for the diagnosis of probable IA was the detection of serum galactomannan antigens. (B) Unreliable BG profile (N = 5 of 37): patients showing alternating negative or low BG test results after IA diagnosis. The kinetics shown are those of Patient 2 (hematology patient), who received a diagnosis of probable pulmonary IA, for whom 2 BG assays were performed before diagnosis and 8 BG assays were performed within 16 weeks of diagnosis. The first mycological result allowing for diagnosis of probable IA was the detection of serum galactomannan antigens. (C) Rapid BG decrease profile (N = 6 of 37): patients with positive BG kinetics after IA diagnosis, who showed a rapid decrease in the BG level, with BG negativation in less than 1 month. The kinetics shown are those of Patient 7 (hematology patient), who received a diagnosis of probable pulmonary IA, for whom 2 BG assays were performed before diagnosis and 8 assays were performed within 13 weeks of diagnosis. The first mycological result allowing for diagnosis of probable IA was the detection of serum galactomannan antigens. (D) Slow BG decrease profile (N = 14 of 37): patients with positive BG kinetics after IA diagnosis, who showed persistently elevated BG levels for more than 3 months. The kinetics shown are those of Patient 32 (solid organ transplant), who received a diagnosis of proven multisite IA, for whom 15 BG assays were performed within 33 weeks of diagnosis. The first mycological result allowing for diagnosis of proven IA was a culture of a skin biopsy that tested positive for Aspergillus fumigatus.